TrialPanorama/TrialPanorama-database huggingface dataset:
Study: NCT06203015

Intervention type: DIAGNOSTIC_TEST
Intervention: The Cambridge Neuropsychological Test Automated Battery.
Description: to determine cognitive dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: The Cambridge Neuropsychological Test Automated Battery.
Description: to determine cognitive dysfunction

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples
Description: to measure levels of cytokines, endotoxin, and genetic markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: Venous blood samples
Description: to measure levels of cytokines, endotoxin, and genetic markers.

Intervention type: DIAGNOSTIC_TEST
Intervention: brain MRI
Description: to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations

Intervention type: DIAGNOSTIC_TEST
Intervention: brain MRI
Description: to evaluate BBB permeability to water, brain structure volumes, white matter integrity, cerebral perfusion, and neurometabolite concentrations

Intervention type: DIAGNOSTIC_TEST
Intervention: the Montgomery-Åsberg Depression Rating Scale
Description: to measure severity of depressive symptoms

Intervention type: DIAGNOSTIC_TEST
Intervention: the Montgomery-Åsberg Depression Rating Scale
Description: to measure severity of depressive symptoms

Intervention type: OTHER
Intervention: questionnaire prepared by the researchers
Description: collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.

Intervention type: OTHER
Intervention: questionnaire prepared by the researchers
Description: collecting sociodemographic data and information about smoking status, BMI, data on the course of MDD, past treatment, comorbid diseases, and current use of medications.
Study: NCT05893628

Intervention type: OTHER
Intervention: muscle length and muscle endurance assessment
Description: Pectoralis Minor Length and muscle endurance evaluation
Study: NCT05324358

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Ketorolac Tromethamine
Description: Ketorolac tromethamine, alcohol free formulation, 1.0 mg/mL in saline solution (\~0.9% NaCl) adjusted to a pH of \~7.4. Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL of NTM-001).

Intervention type: DRUG
Group type: ACTIVE_COMPARATOR
Intervention: Morphine Sulfate
Description: Morphine single use vials at 4 mg/mL, filled with 1 mL.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: Intravenous Placebo for NTM-001
Description: Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: Intravenous Placebo for NTM-001
Description: Placebo alcohol free saline solution (\~0.9% NaCl; matching active NTM-001). Contained in a sterile, 200 mL polyolefin bag (filled with 125 mL Placebo solution).

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: IV Placebo for Morphine
Description: Placebo single use vials with saline (matching active morphine).

Intervention type: OTHER
Group type: PLACEBO_COMPARATOR
Intervention: IV Placebo for Morphine
Description: Placebo single use vials with saline (matching active morphine).
Study: NCT06498349

Intervention type: PROCEDURE
Group type: OTHER
Intervention: bilateral high frequency deep brainstimulation of the subthalamic nucleus combined with best medical treatment
Description: according to widely accepted expert consensus paper

Intervention type: DRUG
Group type: OTHER
Intervention: best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
Description: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.

Intervention type: DRUG
Group type: OTHER
Intervention: best medical treatment (BMT): Adjustment of the dopaminergic medication and non-dopaminergic therapy customized for each patient according to the latest published Consensus Group Recommendations
Description: according to (Debove et al (2024), 'Management of Impulse Control and Related Disorders in Parkinson's Disease: An Expert Consensus, Mov Disord.
Study: NCT06555406

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Time-restricted eating for 8 weeks
Description: limiting food intake to 10 hours per day
Study: NCT05330897

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Implantation of an eCLIPs™ device
Description: Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: eCLIPs™ Electrolytic Bifurcation Systems
Description: Implantation of an eCLIPs™ device and coiling of the bifurcation aneurysm
Study: NCT06487611

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: A humanoid social robot
Description: A humanoid social robot-mediated programme, including human-robot interactions, listening songs and daily news, doing physical activities and play memory games
Study: NCT05730023

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Active tDCS
Description: Active tDCS (anode will be applied over the left DLPFC with the cathode over the right supraorbital region);

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: individualized language training
Description: individualized language training
Study: NCT05951296

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: Leramistat
Description: Drug: Leramistat

Intervention type: DRUG
Group type: PLACEBO_COMPARATOR
Intervention: Placebo
Description: Placebo comparator
Study: NCT06108960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Proprioceptive neuromuscular facilitation
Description: Group A (Proprioceptive neuromuscular facilitation.) will be treated with Proprioceptive neuromuscular facilitation, before applying exercise, Hot pack will be applied for 15 minutes. (8 weeks, 4 sessions per week) The patients will be positioned in supine lying and then contract relax will be performed on affected side of pelvis first in D1 pattern (anterior elevation and posterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. Then in D2 pattern (posterior elevation and anterior depression) 3 times with 10 sec contractions and 5 sec relaxations in 1 set. 3 set of each diagonal pattern to be performed in 1 treatment session alternatively. Treatment will be given for a period of 4 days a week for 8 weeks
Study: NCT05730023

Intervention type: BEHAVIORAL
Group type: ACTIVE_COMPARATOR
Intervention: individualized language training
Description: individualized language training

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: Placebo tDCS
Description: Placebo tDCS (the current will be turned off 10 seconds after the beginning and turned on for the last 10 seconds of the stimulation period);
Study: NCT05370651

Intervention type: DEVICE
Group type: ACTIVE_COMPARATOR
Intervention: BTL Emsella Chair
Description: Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: BTL Emsella Chair
Description: Subjects will sit on the device. The clinical research coordinator will turn the device on and increase the setting gradually until the patient reaches their sensory threshold. This is the maximum sensation the patient can tolerate. The treatment threshold should be increased until the subject reaches 100%.
Study: NCT05308537

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Mindful Compassion Care Program
Description: The intervention is a proven effective mindfulness programme based on well-known scientific programmes such as mindfulness-based stress reduction mindfulness-based cognitive therapy and compassion focused therapy.
Study: NCT05917899

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Virtual Family-Centered Rounds
Description: The care team will use a computer with a speaker camera, mounted on a stand with wheels to launch telehealth visits using the application ExtendedCare. This platform meets HIPAA security rules and launches from the patient's electronic health record. From within this telehealth visit, a care team member will send a message (via text or email) to the parent(s) that includes a link that can be clicked to open a browser that allows the parent to join the telehealth visit. Parent do not need to download or use an application. The care team will invite the video interpreter to join the visit if a parent is present. Family-centered rounds will then proceed in usual fashion with the care team and \[if in attendance\] parent(s). Parents can participate in virtual family-centered rounds as much, or as little, as they choose.
Study: NCT04746391

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Dialyzer type
Description: Fiber blocking and dialyzer clearance is calculated in two different commercially available dialyzers

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Dialysis duration
Description: Fiber blocking and dialyzer clearance is calculated for three different dialysis durations
Study: NCT05907174

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siyakhana - P
Description: A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Siyakhana - P
Description: A trained peer recovery coach (PRC) will be integrated onto the healthcare worker team randomized to Siyakhana - P. The PRC on this team will work with eligible and consenting patients who are seen by members of this healthcare team.
Study: NCT05927818

Intervention type: DIAGNOSTIC_TEST
Group type: EXPERIMENTAL
Intervention: Sentinel lymph node biopsy (using sterile charcoal stain) in early ovarian cancer
Description: Described in previous sections
Study: NCT05583422

Intervention type: GENETIC
Group type: EXPERIMENTAL
Intervention: DPYD or UGT1A1 variants
Description: any CLIA certified lab can be used for confirmatory testing after patients have been identified through Michigan Genomics Initiative (MGI)
Study: NCT05497830

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: RISK-INDEX
Description: Presentation of RISKINDEX to the physician after approximately 2 hours. The ML RISKINDEX is a prediction model based on laboratory data from the ED. It is based on date of birth, sex and at least four laboratory data which are sampled within the first two hours of the ED visit. Laboratory data that are used as input include samples that are commonly drawn in patients that require treatment from an internal medicine physician, such as urea, albumin, C-reactive protein (CRP), lactate and bilirubin.
Study: NCT05990179

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Genome sequencing-based newborn screening
Description: Dried blood spots collected at birth for routine newborn screening will be used for genome sequencing based screening of a defined set of conditions.
Study: NCT05592665

Intervention type: OTHER
Group type: OTHER
Intervention: Survey Questionnaire
Description: Study participants will complete several questionnaires/assessments via PRO-Core standardized email communication or via telephone with a study team member.
Study: NCT06108960

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Pelvic stabilization exercises
Description: Group B (Pelvic stabilization exercises) will be treated with Pelvic Stabilization Exercise, before applying exercise we will apply Hot pack for 15minutes (8 weeks, 3 sessions per week).~All participants will receive training programs for the eight levels of training from static to dynamic conditions. The practiced therapy method will first be taught by a physical therapist with a verbal explanation and visual aids (such as photographs) in each group. The therapist will supervise all stages of the exercise therapy to ensure the patients correctly performed the exercises. The supervised exercise intervention will be conducted 3 days a week for 8 weeks.
Study: NCT05198921

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: repetitive Transcranial Magnetic Stimulation
Description: To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: repetitive Transcranial Magnetic Stimulation
Description: To apply the rTMS will be used the device Neuro-MS/D Variant-3 therapeutic advanced (Neurosoft, Russia) with double cone shape coil. The coil will be placed at Cz according to 10-20 system.~The rTMS protocol will be:~Train frequency - 10 Hz Train duration - 10 sec Inter train interval - 50 seconds Number of train - 25~------------------------------------- Total pulses - 2500 Total session duration - 1500 seconds

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation

Intervention type: DEVICE
Group type: SHAM_COMPARATOR
Intervention: sham repetitive Transcranial Magnetic Stimulation
Description: Neuro-MS/D magnetic stimulator (Neurosoft, Russia) with Neuro-MS.NET software will be used. The synchronous sound will be performed using monitor speaker connected to magnetic stimulator via trigger unit and located near discharging coil. The 10-Hz electrical stimulation will be given trough electrodes fixed on the head along the front edge of the coil to mimic the sensation
Study: NCT05670093

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Neural Pressure Support (mode of mechanical ventilation)
Description: Nasogastric tube will be removed and replaced by a Esophageal catheter and Electrical Diaphragm activity catheter and mechanical ventilation in mode Neural Pressure Support
Study: NCT05954130

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Education
Description: Sexual Health in Pregnancy
Study: NCT05545930

Intervention type: PROCEDURE
Group type: ACTIVE_COMPARATOR
Intervention: Hand Wrung
Description: Hand wrung refers to manually wringing surgical sponges by hand.

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: ProCell Wrung
Description: ProCell wrung refers to automated wringing surgical sponges by an FDA approved suction device (ProCell).
Study: NCT04718415

Intervention type: DRUG
Group type: EXPERIMENTAL
Intervention: sintilimab, paclitaxel, carboplatin
Description: Patients receive sintilimab IV on day 1, paclitaxel IV on day 1 and carboplatin IV on day 1 . Treatment repeats every 21 days for up to 2 - 4 courses in the absence of disease progression or unacceptable toxicity.

Intervention type: PROCEDURE
Group type: EXPERIMENTAL
Intervention: Surgical resection
Description: Surgical therapy will be at the discretion of the treating surgeon per standard of care.
Study: NCT06147986

Intervention type: BIOLOGICAL
Group type: EXPERIMENTAL
Intervention: Allogeneic umbilical cord mesenchymal stem cells
Description: UMSC01 cells will be IC infusion followed by IV infusion with 24 months of follow up after treatment.

Intervention type: OTHER
Group type: OTHER
Intervention: Control group
Description: Standard-of-care for STEMI
Study: NCT06177483

Intervention type: DIETARY_SUPPLEMENT
Group type: ACTIVE_COMPARATOR
Intervention: 95% curcumin extract powder
Description: 95% curcumin extract powder

Intervention type: DIETARY_SUPPLEMENT
Group type: EXPERIMENTAL
Intervention: curQ+ curcumin formulation
Description: curQ+ curcumin formulation
Study: NCT05423886

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: Personalized screening invitation interval
Description: Time to receive the next invitation for fecal immunochemical testing screening, will depend based on individuals risk determined by fecal Hemoglobin concentration
Study: NCT06357247

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Sensory Threshold
Description: Using a light, vibrotactile noise device on the participant's affected wrist. The actuator will be positioned on both the dorsal and volar sides of the wrist. Each participant's sensory threshold will be measured using the method of ascending and descending limits

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Nine Hole Peg Test
Description: The Nine-Hole Peg Test (NHPT) is considered as a gold standard measure of manual dexterity and most frequently used in MS research and clinical practice. The score for the 9-HPT is an average of the four trials. The two trials for each hand are averaged, converted to the reciprocals of the mean times for each hand and then the two reciprocals are averaged. On average, healthy male adults complete the NHPT in 19.0 seconds (SD 3.2) with the right hand, and in 20.6 seconds (SD 3.9) with the left hand.

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Semmes Weinstein Monofilament Assessment
Description: A non-invasive, low-cost, simple, and accurate handheld calibrated nylon thread that buckles once it has delivered a force of 10 g. It provides a standardized measure of a patient's ability to sense a point of pressure. The filaments are classified from grade 1 to 5 according to their thickness: 1.65-2.83 = grade 5, 3.22-3.61 = grade 4, 3.84-4.31 = grade 3, 4.56-6.45 = grade 2, and 6.65 = grade 1.
Study: NCT05864274

Intervention type: DEVICE
Group type: EXPERIMENTAL
Intervention: Cognitive training application
Description: Patients will participate with a cognitive training application and undergo neurocognitive testing during and after chemotherapy.
Study: NCT04844827

Intervention type: GENETIC
Intervention: Conserving routinely performed pleural biopsies in our biological resources center to realize multiomics and bioinformatics analyzes secondarily
Description: Interventions will consist of a diagnostic and symptomatic videothoracoscopy in patients with pleural metastasis under general anesthesia, as part of a standard of care procedure. Fragments of these pleural biopsies (one for routine diagnosis and two for scientific purposes) will enrich the biocollection. Five blood samples will be taken at the time of surgery (3 to 5 ml / tube). These biological samples will be stored in the HCL CRB tumor bank. At the same time, patient demographic data will be collected and anonymized. In the long term, the biological material will be used by IARC for carrying out multi-omics and bioinformatics analyzes
Study: NCT05220618

Intervention type: BEHAVIORAL
Group type: EXPERIMENTAL
Intervention: Autobiographical Memory Specificity and Savoring Training: PESCAR
Description: An autobiographical memory specificity and savoring training has been developed by authors, based on previous training within the frame of Cognitive Bias Modification Interventions (CBM-I; Barry et al., 2019; Hitchcock et al., 2017) and savoring interventions (Bryant et al., 2005; Hanson et al., 2023). The training group will receive a self-guided intervention, which consists of an initial session (lasting 20 minutes approximately) and two-week training, conducted online. Participants will be provided with an online platform for following the intervention in a self-guided modality. The first session aims to give information about autobiographical memory functioning, to train in specificity recall through concrete processing steps and to explain the functioning of the self-guided modality. Then, during the next two weeks, participants will use the online platform once a day for practising the recall of autobiographical memories during 10-15 min approximately.
Study: NCT05997225

Intervention type: OTHER
Group type: EXPERIMENTAL
Intervention: opt out enrollment, tailored counseling, varenicline started prior to target quit date
Description: Participants automatically enrolled in motivational counseling. Tailored counseling includes sharing results of Chest CT results and lung function spirometry tests with participants.

Intervention type: OTHER
Group type: ACTIVE_COMPARATOR
Intervention: opt in enrollment, non-tailored counseling, varenicline started prior to target quit date
Description: Participants must opt-in to receive counseling. Counseling does not include discussion of Chest CT or spirometry results.